Dechra Veterinary Products has launched Ketodale, an anti-inflammatory injection for cattle, horses and swine.
Ketodale contains the non-steroidal anti-inflammatory drug ketoprofen 100mg/ml. It is indicated for use in cattle and swine for diseases associated with inflammation, pain or fever. In cattle these include respiratory diseases, mastitis, osteoarticular and muscular-skeletal disorders, such as lameness and arthritis, and to ease pain post parturition. Ketodale can be used to treat swine suffering from Mastitis Metritis Agalactia (MMA) Syndrome and respiratory tract infections.
In horses, Ketodale is indicated for diseases affecting the osteoarticular and muscular-skeletal system associated with pain and inflammation. These include naviculitis, arthritis and laminitis. It can also be used for post-surgical inflammation and symptomatic therapy of colic and fever.
Ketodale is available in 50ml and 100ml vials.
To coincide with the product's launch, Dechra is carrying out a direct marketing campaign. Practices can take advantage of a special launch offer where they can purchase four vials and get a fifth free. The offer is available for a limited period only.
To find out more about Ketodale, call Dechra on 01743 441 632 or visiting www.dechra.com
VetCell is celebrating a win at Cheltenham, after 'Knowhere' won the Cotswold Chase following pioneering stem cell treatment for a serious tendon injury.
Knowhere had had a good start to his racing career as a four-year-old, winning his first two races as a novice hurdler. But after his second race in 2004 he suffered injuries to both forelimb superficial digital flexor tendons. The left fore showed low grade tendonitis while the right fore had a significant percentage of fibre rupture. As a promising racing prospect, Knowhere’s connections wanted to give him the best possible chance of recovering from his injury so they opted for stem cell therapy. He was treated by Tim Beauregard MRCVS of Summerhill Farm in Gloucestershire.
Bone marrow samples were collected from Knowhere’s sternum and were processed in VetCell's laboratory over a five week period to generate millions of stem cells. Knowhere was sedated, the tendon area was anaesthetised and the leg was then surgically clipped and disinfected. Stem cells, which had been suspended in serum obtained from the original bone marrow sample, were then injected using ultrasound guidance, into the core of the damaged area of the tendon fibres.
For the first week after the implantation Knowhere was kept in his stable to allow the cells to adapt to their new environment. Each day after this he was given walking exercise in order to stimulate the activity of the stem cells, encouraging them to differentiate into tendon cells and form into strong tendon fibres. The amount of exercise was incrementally increased, building up over a three-month period from five minutes each day to 45 minutes twice a day.
By the autumn of 2005 both of Knowhere’s tendons had healed very well and showed good fibre pattern on ultrasonography. He was re-introduced to the racetrack the following year and of the 15 or so races he has been in since, he has finished in the frame on eight occasions and has amassed some £175,000 in winnings.
Vet Tim Beauregard said: “Knowhere’s successful return to the track has been exciting and immensely satisfying to follow and he showed particularly brilliant form in the Cotswold Chase. It remains to be seen whether he will be heading for the Ryanair Chase, the Gold Cup or the Grand National but all involved will be hoping for the best.”
For more information please contact VetCell on +44 207 691 2062 or 866 764 0340, email: info@vetcell.com or visit the website at http://www.vetcell.com/
Dunlops has changed its name to Henry Schein Animal Health.
David Hinton, Managing Director said: "As we change our name to Henry Schein Animal Health, we also reaffirm our company's strong commitment to offer a comprehensive array of products and services to help animal health practitioners in the United Kingdom operate more efficient and successful practices, and provide the best quality patient care.
"We have a new name, but we have the same strong team, the same values, and the same dedication to providing excellent service to our customers."
Henry Schein Animal Health’s expanded offerings include VetLink and Thrive. VetLink is a new e-commerce web site system that enables veterinary surgeons to access the growing internet sector, allowing you to sell anything from pet prescriptions to accessories online, to be delivered to your customers’ homes by Henry Schein Animal Health. Thrive is a new veterinary business analysis service that integrates with practice management software to use a Key Performance Indicator based approach that provides insight into a your practice and identifies areas where you can enhance your business.
The initiative comes after BEVA's new nurse committee ran a survey which found a poor understanding within the profession and amongst clients of what equine nurses can do.
Nurses said they believed they could be given more responsibility and do more within their roles and that there was a lack of opportunity for progression.
BEVA President David Rendle, who is championing this initiative, said: “RVNs are a significant an asset to any equine practice.
“They have invested a lot of time and effort to become highly skilled but in some instances their significant attributes are not being utilised to the full.
“Allowing RVNs to perform the clinical tasks that they are qualified to carry out under Schedule 3 of the Veterinary Surgeons Act 1966, will provide better job fulfilment and career development as well as free up veterinary surgeons to carry out other tasks, all increasing the efficiency of the veterinary team.
“I feel, and the RVN survey results would seem to confirm, that veterinary surgeons and practice managers do not appreciate how much veterinary nurses are allowed to do in equine practice.
"We all know veterinary nurses have the ability; look at what they do in small animal and human nursing, but we have felt unnecessarily constrained by Schedule 3 of the Veterinary Surgeons Act 1966 and the associated RCVS guidelines.
"If you actually look at Schedule 3 it is clear that we can and should be letting our qualified equine nurses do far more.
“There are so many things in equine practice that nurses do better than vets.
"In addition to performing clinical tasks they can add wider value; they are generally (or are perceived by clients to be!) more patient, empathetic and caring so we should utilise these skills and get nurses to take on some of the roles that take more time and require longer client interactions – discussing parasite control programmes, running weight loss clinics, reviewing healthcare plans, making follow-up phone calls and visits to name just a few.
"Nurses can take a lot of pressure off vets and can add a significant revenue stream for the practice.”
On the 9th February, the BEVA will be hosting an online discussion forum for all members of the practice team to discuss the role of nurses and how their skills, experience and knowledge can be better-used.
It's free for BEVA members: https://www.beva.org.uk/Home/Events/BEVA-Events/Event-Details.aspx?eventDateId=1716
Marie Rippingale Chair of the BEVA Nurse Committee said: “Last year’s recruitment and retention survey revealed that 50% of nurse respondents were earning less than £25,000 per annum and 48% of nurses said they were likely to look for a new job in the next two years.
"When asked their top reasons for leaving, salary was the biggest reason, and common themes on what would help the retention of nurses included salary, work-life balance and career progression.
“The review of Schedule 3 is important so we can encourage delegation of tasks to RVNs.
"This will allow RVNs to demonstrate their value and worth, earning money for the practice and achieving job satisfaction at the same time. This will contribute positively towards the current retention crisis.”
To find out more about what equine veterinary nurses can do in practice visit https://www.beva.org.uk/nurses
Photo: Liphook Equine Hospital.
The event is held every four years and hosted alternately by BEVA and the American Association of Equine Practitioners (AAEP).
It offers the opportunity for equine vets to absorb and digest the latest knowledge, clinical practice and scientific advances in the treatment and prevention of colic, from the world’s leading international equine gastroenterology experts.
Held over 2.5 days, the symposium comprises numerous 12-minute oral presentations on a range of topics including surgical techniques, treatment, parasitology, gastric ulceration, endotoxemia, pharmacology of intestinal motility, colic complications, epidemiology, physiology of digestion, the intestinal microbiome and metabolomics.
Each session will be followed by three minutes for questions and discussion.
Poster sessions on the first two days will cover ground beyond the oral presentations and delegates will be able to review and discuss the work with presenters.
There will also be opportunities to network with other equine vets, researchers and professionals.
Clinicians and scientists have until 1 February 2024 to submit abstracts of recent work that they wish to present at this meeting.
The scientific committee will consider abstracts on all aspects of equine gastroenterology, including basic science research and reports of clinical cases or novel approaches to treatment.
The abstract submission form is here: https://form.jotform.com/230473925626359
Tickets cost £475 (with a concessionary rate of £235 for post graduate students and interns) and includes a drinks reception on both 10th & 11th, an evening buffet and Ceilidh on 11th and lunch on 11th & 12th.
Further information and booking details can be found here: https://www.beva.org.uk/Education/CPD/Event-Details/eventDateId/1740
Congratulations to Merial for a creative initiative to celebrate the 25th birthday of Eqvalan®.
The company made a much needed donation towards the upkeep of the Pewsey White Horse in return for being able to use it as part of Eqvalan's birthday celebration publicity programme for 2008.
The money will be used to restore the protective fencing around the ancient landmark, near Marlborough in Wiltshire.
Merial's Claire Parry- Baggott explains: "There are a number of white horse sites across the UK, many of which are extremely popular visitor destinations. To keep these sites open to the public requires year-round maintenance, often from a small army of volunteers.
"Horse owners have been using Eqvalan to help protect their trusty companions for 25 years, and this initiative will help provide protection of a different kind!
"The idea sprang from the current Eqvalan advertising campaign which celebrates 25 years of worming protection. The result is a fantastic 100 feet replica of our Eqvalan birthday horse, and brand new fencing for the Pewsey White Horse!
"We were delighted to help the Pewsey Council raise funds to preserve the site and hopefully this money will enable the horse to be enjoyed by many for years to come," concludes Claire.
A research project funded by The Horse Trust has made important discoveries about how two peptides regulate the inflammatory response in horses. This knowledge could help with the development of improved anti-inflammatory drugs, which are used to treat a wide range of conditions in horses.
The research project was led by Professor Fiona Cunningham at the Royal Veterinary College in Hertfordshire and Dr Karen Rickards at the Donkey Sanctuary in Sidmouth, assisted by Dr Andrew Brooks at the RVC, and by Dr Kirstie Pickles, now at the Royal (Dick) School of Veterinary Studies in Edinburgh.
Inflammation is associated with a wide range of equine diseases, including recurrent airway obstruction, laminitis and sweet itch. Anti-inflammatory drugs, such as glucocorticosteroids, mainly work by blocking the formation and/or actions of compounds produced in the horse's body that cause inflammatory responses. However, these drugs are not always effective and can have unwanted side effects.
This research, funded by The Horse Trust, aimed to find out more about two naturally-occurring peptides - chains of amino acids that are shorter than proteins - known as annexin-1 and CXCL8. Both have been shown to affect the inflammatory response but little research has been done on their effects in horses. In the long term, knowing more about these compounds could help in the development of new anti-inflammatory drugs with fewer side effects.
During inflammation, neutrophils (a type of white blood cell) stick to the cells lining blood vessels and migrate into inflamed tissue, where they ingest and break down harmful agents. Using techniques that mimic these events, CXCL8 was found to cause adherence and migration of horse neutrophils. However, when it was used in combination with another pro-inflammatory substance, neutrophil migration and adherence were markedly decreased. This suggests that attempts to reduce inflammation by blocking the actions of CXCL8 might not be as beneficial as had been thought.
At the start of the project, the researchers had no information about horse annexin-1, other than its gene sequence, so their first step was to develop a method to detect the peptide in white blood cells. They established that it was present and, as horse annexin-1 has not yet been synthesised, they used a synthetic peptide derived from annexin-1, Ac2-26, to look at the effects on horse neutrophils.
They found that Ac2-26 decreased neutrophil adherence and migration in response to other pro-inflammatory compounds, although at high concentrations the peptide itself caused some cell activation, thereby increasing inflammation. They also found that dexamethasone (a glucocorticosteroid) increased the levels of annexin-1 in cells, indicating that, as in humans, this class of drugs is likely to act in part through the formation of annexin-1.
These findings suggest that the use of compounds which mimic the actions of annexin-1 may have limitations as anti-inflammatory drugs. As glucocorticosteroids partly work by forming annexin-1, further research is needed in order to find out how annexin-1 will act in the horse's body and establish how its formation contributes to the beneficial effects of these drugs.
Professor Cunningham said: "This Horse Trust-funded research has resulted in some very interesting findings about how inflammatory cells are regulated in horses. The receptors that annexin-1 and CXCL8 act upon could be targets for new equine inflammatory drugs, but more research is needed first to fully understand their actions and how they produce these effects."
The team's research has been accepted for publication by the journal Veterinary Immunology & Immunopathology.
The review, announced earlier this year, was recommended to RCVS Council by its Standards Committee following its exploration of the implications of new technologies for both animal health and welfare and veterinary regulation.
The main areas under consideration include the provision of 24-hour emergency cover and the interpretation and application of an animal being under the care of a veterinary surgeon.
The initial stages of this review had been drafted for Standards Committee to consider at its meeting on 9 September, where the outline timetable was also discussed.
Standards Committee Chair Melissa Donald, said: "This is set to become one of our most fundamental reviews of RCVS guidance in recent years.
"Considering the complexity of the issues in question, and their importance to animal owners and the professions alike, it is vital that we allow ourselves enough time to ensure this review is as thorough and comprehensive as possible.
"We have a clear responsibility to seek, understand and, where we can, accommodate the opinions and experiences of as many different people from within and around the professions and the public as possible. I would urge my fellow vets and vet nurses to please find some time to consider these issues very carefully over the coming weeks and months, and to send us their views."
The review will comprise several stages and is expected to take around 12 months to complete. The outline timetable, which may be subject to change, is as follows:
October 2019 – January 2020: six-week Call for Evidence, followed by independent qualitative analysis of all evidence received
February – March: Select Committee-style meetings and independent qualitative analysis of additional evidence gathered [NB this stage is subject to Standards Committee requirements, depending on the evidence gathered.]
April – June: Consider all evidence and draft any new policy
July – August: six-week public consultation on draft policy
September – October: independent review of consultation responses, and production of any proposals for change
November 2020: Finalise any proposals for change and publish any new guidance
To support and promote the various stages of the review the College is also planning a programme of stakeholder engagement, and will also provide regular updates on progress to both Council and the wider profession.
Members of the professions and the public will be able to follow the progress of the review via the RCVS website at: www.rcvs.org.uk/undercare
The apple-flavoured, gastro-resistant granules can be mixed with dry feed to make administration easier for owners.
Animalcare says that up to 37% of leisure horses and 93% of race horses are reported to be affected by gastric ulcers1, for which the most prescribed treatment is omeprazole.
Equizol’s granule formulation has been developed to support owners who find syringe administration difficult or wasteful. It is presented in packs of 28 sachets, each containing sufficient omeprazole to treat 200 kg body weight. Owners mix the appropriate number of sachets into a small amount of the horse’s feed.
Animalcare Product Manager James Beaumont said: “Offering innovative product solutions which better meet our customer’s needs is our goal and Equizol is a perfect example. Our established equine healthcare range includes products for pain management, infusion therapy and microchips. Now, with the launch of Equizol, we are offering an innovative, easy-to-use and cost-effective solution to the common problem of gastric ulcers, based on tried and trusted omeprazole. We are delighted to add it to our range.”
Reference
The study, titled ‘Physics of animal health: On the mechanobiology of hoof growth and form’, represents the fruit of a collaboration between researchers in equine medicine, maths, physics and stem cell biology. It was conducted by the School of Veterinary Medicine and Science at University of Nottingham in collaboration with the Waltham Centre for Pet Nutrition and the Royal Veterinary College.
Lead author Dr Cyril Rauch said: "With new scientific inputs from physics, mathematics and biology, this study provides an entirely new paradigm regarding hard growing tissues such as the horse hoof, which can be applied across cattle, sheep and other species, to unify a set of apparently disparate conditions and clarify the roles of physics and/or biology."
Using hooves from horses euthanased for non-research purposes, the study revealed how it is possible for the hoof growth rate to be greater than the potential proliferation rate of epithelial cells. It also explained how the synthesis of the hoof capsule starts from the coronet and that the soft papillae undergo gradual transition through three interpapillary regions into hard keratinised tissue.
Mathematics, physics and cell biology were then used in the study to explain and describe how the dorsal hoof wall can grow in a curved manner rather than the usual straight manner as a result of faster growth from the coronary band at the quarters compared to the toe region.
Evaluation of the feet from live underweight and obese subjects (assessed using Body Condition Scoring) allowed the influence of body weight on the balances of the stresses affecting hoof growth to be evaluated. The results suggest that being proportionally heavier may promote straighter hoof growth and that being too lean may precipitate poor hoof growth and the development of a hoof with a dorsal curved shape.
The study also showed that a high concentration of insulin stimulated equine progenitor keratinocytes (the outermost layer of cells on the hoof wall) to grow in culture. If this also happens chronically within the live animal, it is possible that it could affect the growth stresses within the hoof and so promote a dorsal curved hoof shape.
Co-author Nicola Menzies-Gow said: "These results taken together can explain how the hoof grows and how it is possible for it to develop a dorsal curvature. However, it should be acknowledged that this does not take into account the genetic or metabolic influences on hoof growth nor the role of hoof trimming and shoeing in maintaining a mechanically healthy hoof. It is appreciated that the underlying biology of hoof growth remains an essential factor for hoof pathologies."
Dr Cyril Rauch continued: “Given that the hoof is a weight bearing element it is essential to untangle the biology from the physics in this system; only then can meaningful biological and/or physical causes be prescribed for particular hoof shape. Removing the cause(s) when physically or biologically possible is essential to resolve hoof conditions."
The British Equine Veterinary Association (BEVA) has clarified regulations on equine dental procedures following a survey which showed confusion, even amongst vets, over who is allowed to do what in a horse's mouth.
In the survey of BEVA members, more than half were unaware of the dentistry techniques that equine dental technicians (EDTs) are permitted to perform and the levels of veterinary supervision required.
In response, the association has put together a new information leaflet which explains the regulations surrounding equine dental care and describes where recommended practice differs from the letter of the law.
All diagnostic and treatment procedures in the horse's mouth are Acts of Veterinary Surgery under the Veterinary Surgeons Act 1966. The only exception is the manual removal of small dental overgrowths and sharp enamel points with hand instruments.
However it is acknowledged that there are a limited number of procedures that, despite being considered Acts of Veterinary Surgery, may be delegated safely to suitably qualified EDTs without compromising the horse's welfare and safety. In 2009 the RCVS, with assistance from BEVA, BVDA and BAEDT, listed these processes and categorised all dental procedures into three groups:
Despite there being no legal basis supporting non-vets performing Category 2 procedures, the RCVS has stated that there would be no public interest in prosecuting vets who collaborate with suitably qualified EDTs to perform non-invasive (Categories 1 and 2) procedures.
BEVA recommends that, for their own protection, all vets who deal with horses:
Vicki Nicholls, equine vet at Wright and Morten in Cheshire, chair of BEVA council's Paraprofessional Committee and member of the British Association of Equine Dental Technicians (BAEDT) said: "The lack of awareness is alarming and clearly emphasises the need to make vets and equine dental technicians fully conscious of current regulations regarding equine dentistry. Non-adherence to the regulations is a serious matter and could lead to prosecution of the veterinary surgeon, EDT and/or owner."
The number of vets taking the BEVA/BVDA exam in equine dentistry has increased in recent years with about 15% of those who have passed the exam being vets. BEVA says this is indicative of the growing awareness, amongst owners and vets, of the importance of dental health. It also reflects a desire to develop and demonstrate both practical skills and a theoretical understanding of equine dental care to augment the vet's broader medical knowledge. Expertise in equine dental care has, for many veterinary practices, become a valuable asset.
Copies of the dental regulations information leaflet can be downloaded from the BEVA website at www.beva.org.uk. BEVA also runs regular dentistry CPD courses, details of which can be found on the website.
Image source: Rachel C from Scotland
The Horse Trust is funding a three-year project to develop a genetic diagnostic test for Fell Pony Syndrome (FPS) and thus enable control and possible elimination of the disease.
The work will be undertaken at the Animal Health Trust, Newmarket, and the University of Liverpool Veterinary School.
The Fell pony, an ancient British pony breed categorised as "at risk" by the Rare Breeds Survival Trust, has over the past decade or so been subject to a severe immune deficiency known as Fell Pony Syndrome (FPS), which results in the death of some of the newborn foals.
Foals affected with FPS appear normal at birth but within a few weeks begin to lose condition and suffer diarrhoea, coughing and weight loss. Severe anaemia and immune dysfunction follows, leading to wasting and finally death. The disease is always fatal.
As a large percentage of these ponies live and breed on the fell, the prevalence of FPS is unclear. Despite an improvement in foal registration numbers in recent years, Fell Pony Syndrome remains of concern to breeders.
Studbook analysis and knowledge of affected foals strongly suggests that this is an inherited disease caused by an autosomal recessive genetic mutation. A DNA based test for this mutation would enable carriers of FPS to be identified and the conception of affected foals prevented.
As well as identifying carriers in the Fell pony population, the project will be used to identify any carriers in other breeds which have been involved in the extensive outbreeding of Fell ponies over the years.
"The success of this project will prevent the suffering of newborn Fell pony foals affected with FPS," says project leader Dr June Swinburne, senior post- doctoral equine molecular geneticist at the Animal Health Trust Centre for Preventive Medicine. "Foals affected by the condition inherit an incurable genetic defect which results in severe wasting and a profound anaemia together with multiple infections. Veterinary intervention is in vain and once the condition is diagnosed foals are often euthanased. The gradual but relentless decline in these foals leaves both veterinary surgeons and breeders powerless.
"Breeders are supportive of our attempt to develop a diagnostic test which will help to prevent carrier-carrier matings, one in four of which results in an affected foal."
The Horse Trust's Chief Executive and resident veterinary surgeon Paul Jepson said: "This is an exciting and achievable project with significant benefits for equine health and welfare, as it will lead to the prevention and elimination of a fatal disease."
Dechra Pharmaceuticals PLC has announced that it has acquired the entire issued share capital of Genitrix Limited ("Genitrix") from its owner managers for an initial cash consideration of £5.4 million, with a further £0.8 million being payable upon achievement of specific milestones.
Dechra says the acquisition of Genitrix is consistent with its strategy to grow its international veterinary pharmaceutical business. In the year ended 31 March 2010, Genitrix achieved revenues of £2.4 million.
Ian Page, Chief Executive of Dechra, said: "Genitrix range of equine and companion animal products enhances and complements our UK product portfolio. Furthermore the recently approved canine epilepsy product, Libromide, provides future growth opportunities through potential mutual recognition in Europe. The acquisition is expected to be earnings enhancing in the first full year following ownership."
Fort Dodge has announced that a challenge study has demonstrated the ability of Duvaxyn® IE-T Plus equine influenza vaccine to cross protect against A/equi-2/Sydney/07 (H3N8) two weeks after a two dose primary course. This strain was responsible for the financially devastating equine influenza outbreak in Australia in August 2007.
Duvaxyn IE-T Plus is an inactivated whole virus equine influenza vaccine, adjuvanted with an aqueous-based adjuvant. According to Fort Dodge, experts at a recent WHO meeting on human vaccines expressed the view that whole virus vaccines have the potential to induce a stronger and more broadly based response to circulating influenza strains than those contained in sub-unit vaccines because of the presence of the full set of virus proteins in the vaccine*.
The study, conducted by the Animal Health Trust, involved two groups of EIV seronegative horses. The first group, consisting of seven vaccinates, were given two dose of Duvaxyn IE-T Plus, 28 days apart, and challenged with A/equi-2/Sydney/07 (H3N8) virus strain 14 days after the second vaccination. The second group of unvaccinated horses was challenged at the same time. Duvaxyn IE-T Plus caused a statistically significant reduction in both clinical signs of the disease and in viral shedding.
Helen Barnes, EMEA Equine Business Manager for Fort Dodge, said: "The results of this challenge study provide reassurance for owners that horses vaccinated with Duvaxyn will be protected against circulating strains of equine influenza, including the Sydney strain which proved so damaging.
"As the benefits offered by whole virus technology are increasingly recognised, the popularity of vaccines based on this technology is re-emerging, particularly to combat a potential pandemic.
"The entire Duvaxyn range of equine vaccines, including the recently licensed Duvaxyn WNV for West Nile Virus, are based on the whole virus approach as we believe it offers a broad and consistent level of protection."
Blue Cross has announced the results from its National Equine Health Survey (NEHS) which show that lameness is three times more likely to be caused by conditions such as osteoarthritis in the limb rather than problems in the foot.
Blue Cross runs NEHS in May each year, in partnership with the British Equine Veterinary Association (BEVA). It is sponsored by SPILLERS and Zoetis and supported by the UK’s leading equestrian organisations and charities. This year saw a 35% increase in participation compared to 2014, with survey records returned for almost 15,000 horses, ponies, donkeys and mules.
The charity says that whilst of course the horse’s foot is fundamental to soundness and performance, NEHS results have shown consistently that limb lameness, as opposed to foot lameness, is in fact the biggest syndrome affecting horses.
In the latest survey, conducted in May, a total of 18% were recorded as lame. 13.5% of these were recorded as suffering with lameness such as osteoarthritis, also known as degenerative joint disease (13.9% in 2014 and 14.8% in 2013).
Meanwhile foot lameness was recorded in 4.5% of returns, a similar figure to previous years.
Josh Slater from the Royal Veterinary College, who is member of BEVA’s Health & Medicines Committee and analysed the NEHS data, said: “NEHS is now producing important evidence that is replacing subjective opinion. While the lameness figures were initially surprising, given that the foot has been generally regarded as the main problem area, the fact that these figures have remained consistent over the past three years gives constructive credibility to the data. Our findings will help owner vigilance with day-to-day healthcare as well as help prioritise on areas for future veterinary education and research.”
The six most notable disease syndromes identified in the 2015 National Equine Health Survey were:
23.2% of horses were reported as being overweight with a Body Condition Score of 3.5-5, continuing the upward trend seen in previous years (16.9% in 2014 and 7.8% in 2013). Next year’s survey will explore links between obesity and the possible associated rise of obesity-related diseases such as equine metabolic syndrome (which was reported in 2.4% of 2015 returns) and laminitis.
The survey also enables participants to report on any health problems not covered in the survey questions, giving them a chance to shape future survey subjects.
Gemma Taylor, Education Officer at Blue Cross explains: “This year 11% of our free text answers mentioned gastric ulcers giving a valuable insight into the prevalence gastric ulcer syndrome in the principally leisure horse NEHS population. As a result we will be adding new questions to the 2016 survey to help us find out more.”
The 2015 NEHS survey results are now available from http://www.bluecross.org.uk/nehs2015results. To register for next year’s survey, visit www.bluecross.org.uk/nehs
The ioLight microscope fits in a jacket pocket and the company says it is both simple to use and robust. It unfolds to record and share 5MP still images and real time HD video at a magnification of x200 on an iPad Air. The resolution is 1 micron or 1/1,000 mm, powerful enough to see the structure of plant and animal cells.
The microscope uses standard microscope slides and has adjustable top and bottom illumination for use on both biological and opaque samples.
Iolight says it is particularly good for live samples which deteriorate on the journey back to the lab, and it works anywhere, even without a WiFi or mobile phone network.
Andrew Monk, who founded ioLight with business partner Richard Williams, said: "It takes just a couple of minutes to get a great image on the microscope, anywhere from a river bank to a factory floor. This makes microscopy simpler for everyone, from experienced professionals to student scientists."
The ioLight microscope can be ordered now from www.iolight.co.uk, priced at £840 including VAT.
The new resources include the Equine Veterinary Journal’s (EVJ) publication of BEVA’s Primary Clinical Care Guidelines on wound management in horses together with BEVA’s first ever digital CPD course: 'How to Heal Wounds – a masterclass for vets and vet nurses'.
The new guidelines cover three key areas: wound lavage and topical treatments; wound debridement and closure and therapeutics for wound healing.
Sarah Freeman, who led the project, said: "These guidelines are aimed at the vast majority of our membership who are primary care practitioners. Topics covered are voted for by BEVA’s panel of specialists and represent a benchmark in time against the strength and weakness of evidence that support it."
The wound management guidelines follow BEVA’s recommendations on the safe use of analgesia in horses, which were published earlier this year.
BEVA’s new online course: 'How to Heal Wounds' is aimed at mixed and equine practitioners and veterinary nurses who encounter wounds in horses.
Led by Dr Patrick Pollock BVMS, PhD, CertES(Soft Tissue), DipECVS, FHEA, FRCVS along with teaching from leading names including Professor Derek Knottenbelt OBE, BVM&S, DVM&S, DipECEIM, MRCVS, Dr Dylan Gorvy BSc, BVSc, PhD, CertES(Soft Tissue), DipECVS, and Ms Georgie Hollis BSc it will provide key concepts of wound physiology and introduce new treatment ideas and modalities designed to optimise wound healing.
Tim Mair Chair from BEVA’s Education Committee said: “This course is an absolute masterclass for vets and vet nurses. It contains 12 on-demand recorded lectures, together with the opportunity to attend up to three live discussions with the speakers. The final live discussion will provide the opportunity for the delegates to trouble shoot with our speakers after being able to go and practice the skills and knowledge learnt on the course.”
The course will be available from August 2020. It will cost £65 for BEVA members (£130 for non-members), which includes access to course resources for up to a year – meaning if they can’t attend a live discussion, they can watch it later.
Photo: Dr G Quinn.
The new pass offers both physical and virtual tickets so that the practice rota doesn't have to stop any member of the team from attending.
BEVA says the new tickets also offer a saving of up to £113 per vet.
David Mountford, Chief Executive of BEVA said: “We know that not every vet at a practice can attend congress every year because someone is always going to have to stay behind and work.
"So, by offering a mix of physical and virtual tickets in the pass it means those staying at home to look after the practice can still benefit from the live stream as well as the six-month access to all the lectures afterwards.
"Congress always contains plenty of relevant and dedicated content for nurses, so the pass obviously includes nurse tickets too.”
Practice Passes are available for BEVA members in three packages: small (£599), medium (£1,333) and large (£2,666).
Individual early bird BEVA member prices are £499 for vets and £187 for vet nurses for all three days (with concessions available for those in their first three years’ post-graduation or on a lower salary).
Practice Passes and early bird tickets are available to purchase until Monday 1 August 2022.
Day tickets are also available.
Virtual tickets are £199 for vets and £40 for nurses.
For more information, or to book tickets, visit http://www.bevacongress.org
Boehringer Ingelheim Vetmedica has launched a unique and natural muscle building supplement for horses, Equitop Myoplast Power Pearls, containing 18 key amino acids.
The company says maintaining muscular condition in performance and sports horses can be challenging, especially when work load is increased or during periods of convalescence, as feeding high levels of concentrates can often lead to horses becoming 'fizzy' and bulking up on fats and oils.
Scientifically designed to support lean muscle growth, not bulk, Equitop Myoplast Power Pearls is great for optimising performance in horses in intensive training and competition, as well as bringing on young, breeding and injured animals, and for older horses which lose condition easily.
The product is endorsed by top British show jumper, Ellen Whitaker and veterinary surgeon and dressage rider, Christel Robbins BVSc MRCVS.
Craig Beck from Boehringer Ingelheim Vetmedica said: "Equitop Myoplast Power Pearls is already one of the most popular equine supplements sold in Germany and is used by top riders in all disciplines to help ensure their horses reach their full athletic potential. We are certain that with the support of riders such as Ellen Whitaker, Equitop Myoplast Power Pearls will prove just as popular in the UK."
Equitop Myoplast Power Pearls is available in a 1.5kg tub (RRP £65) and can be fed separately or mixed with feed. Horses weighing less than 500kg should be fed one scoop (25g) per day, while larger horses should receive two scoops (50g). Boehringer Ingelheim Vetmedica recommends that Equitop Myoplast Power Pearls is fed for at least a month as results are normally visible within 3-4 weeks.
Boehringer Ingelheim Vetmedica is committed to supporting veterinary practices and Equitop Myoplast Power Pearls will be distributed exclusively by veterinary wholesalers. An extensive advertising campaign in professional equine publications will help raise awareness of Equitop Myoplast Power Pearls and, for a limited period, horse owners and equine professionals can download a voucher from http://www.equitop-myoplast.co.uk/ offering a £15 rebate against their first purchase. Veterinary practices can redeem these vouchers by returning them to Boehringer Ingelheim Vetmedica via a freepost address.
For further information on Equitop Myoplast Power Pearls, please contact your local Boehringer Ingelheim Vetmedica representative, visit www.equitop-myoplast.co.uk or call 01344 746959.
The awards celebrate outstanding veterinary surgeons and nurses, practices, practice managers and support staff who’ve been nominated by their clients and colleagues for their hard work, dedication and going that extra mile to keep the nation’s pets healthy.
This year, there were over 37,000 nominations. The finalists are:
Practice Support Staff of the Year
Practice Manager of the Year
Practice of the Year
Vet Nurse of the Year
Vet of the Year
James Barnes, head of sales and partnerships at Petplan, said: “We’re delighted to announce the finalists for the annual Veterinary Awards, which honours the exceptional work carried out by some of the best veterinary professionals in the country. Congratulations to all the 2020 finalists on this fantastic achievement.
“We understand that that this remains an extremely challenging time, which is why we would like to bring the veterinary profession together so we can say thank you for your ongoing dedication to the care of pets. This is particularly true when we consider the devoted teams and individuals continuing to care for the nations pet during the COVID-19 outbreak. Whilst we might not be celebrating together in person this year we hope as many people as possible will join us online for this exciting celebratory event.”
The awards will be hosted on Facebook @PetplanUK on Thursday 28th May 8.30pm. For more information: https://www.petplanvet.co.uk/veterinary-practice-insurance/veterinary-awards.
BSAVA Summit will take place from 16-17 December 2019 at the Royal College of Physicians in London and will involve a series of high-profile keynote speakers and interactive workshops.
The Association says the event will deliver CPD differently to other veterinary meetings, with most sessions run as facilitated workshops to enable delegates to lead and shape discussions.
Confirmed facilitators include RCVS CEO Lizzie Lockett, BEVA President Renate Weller, Director of Clinical Research and Excellence in Practice at VetPartners Rachel Dean and Small Animal Medicine Specialist and Advanced Practitioner in Veterinary Cardiology Dr Kit Sturgess. Each day delegates can choose three out of a total of five workshops. Online forums will be used in the run up to BSAVA Summit to develop ideas and thinking for the workshops before the event.
Day one will focus on ‘The Profession Today’ and topics will include workforce issues, telemedicine, specialism, the future of advanced practitioners and regulation of the profession.
Day two will explore the future of ‘The Profession Tomorrow’ with topics including communication, over-diagnosis, over-treatment and innovation.
On the Monday evening delegates, speakers and facilitators will be able to network at a drinks reception in the library at the Royal College of Physicians.
BSAVA President Sue Paterson said: "We have launched BSAVA Summit to address the rising demand for a space to debate important topics, challenge mindsets and question accepted benchmarks. Following feedback from our members and the profession, Summit will revolutionise veterinary conference norms with a free-flow approach to champion active debate, discussion and reflection.
"There is a growing need to tackle some of the ethical and professional problems that face vets today such as over diagnosis, the role of specialists in practice, and research in practice. Importantly, the format of the discussion forums means that whilst the debate is led by a facilitator, the delegates will drive the agenda to arrive at stimulating and satisfying outcomes. It has been designed to fit with the new outcomes-based approach proposed by the RCVS where veterinary professionals are encouraged to plan their CPD, do their CPD and reflect on what they have learnt.
"The delegates are the key to the event, and Summit should attract people who want to be involved, want to input, want to make a difference and want to help drive the profession forward. I already have people eagerly emailing me wanting news of when the registration goes live.
"Summit aims to help delegates take a hard look at the way they work. Our aim is for each delegate to set themselves personal goals and we will be following up in 3 months to see if they have achieved them."
The BSAVA says that although the Summit is primarily targeted at experienced small animal practitioners, all vets, including equine and large animal practitioners, are welcome to attend.
The full programme will be available and registration will open online on 17th June. BSAVA members will have an opportunity to book advance tickets, with general sale opening two weeks later.
For further information visit www.bsavasummit.com.
The effect of changing diet on gastric ulceration in exercising horses and ponies following cessation of omeprazole treatment was conducted by Nanna Luthersson (Hestedoktoren, a private practice in Denmark) and Coby Bolger (Horse1 Spain), with colleagues from the University of Madrid and Glasgow, in collaboration with Spillers and the Waltham Equine Studies Group.
The study evaluated the effect of dietary change in combination with omeprazole treatment and after the cessation of treatment.
The 32 horses in this part of the trial had been diagnosed with significant equine squamous gastric disease (ESGD) and were in hard work.
On a random basis one of each pair was assigned to a specified low starch, fibre-based diet consisting of their own forage alongside a restricted starch, high fibre, high energy cube (Spillers HDF Power Cubes, which are commonly used in racing yards) and a high oil, low starch, chopped alfalfa based feed (Winergy Equilibrium Growth) and the other stayed on their original diet. All animals were scoped before, after the recommended course of omeprazole treatment and then six weeks after the omeprazole finished.
The horses in the no diet change group improved significantly with the omeprazole but when the treatment was stopped many regressed. Overall, by the end of the trial they were not significantly different to when they had started.
However, the horses in the dietary change group overall showed significantly improved ESGD scores, not only following the omeprazole treatment but also after the treatment had stopped. This showed that a change in diet was able to help maintain the beneficial effect of omeprazole even after the omeprazole was removed.
The study achieved an award in 2016 for research in horse welfare from the Fundación para la Promoción del Deporte Ecuestre, Spain.
Clare Barfoot RNutr, the research and development manager at Spillers, said: "This exciting work confirms what we suspected; that whilst appropriate dietary change can provide additional support to medical treatment for EGUS most importantly it can help maintain better gastric health post medical treatment."
Last year the British Equestrian Trade Association, in consultation with the Veterinary Medicines Directorate, introduced a new feed approval mark to help owners identify feeds suitable for horses and ponies prone to equine gastric ulcer syndrome (EGUS).
Currently six feeds in the UK carry the BETA Equine Gastric Ulceration Syndrome (EGUS) Certification Mark including Winergy Equilibrium Growth and Spillers Alfalfa Pro Fibre.
However, despite keeping this POM-V drug to hand, only 7% said they would seek advice for minor wounds and over 25% said they would not contact the vet even if their horse was lame.
This, says the company, raises concerns about the appropriate use of bute in wounded horses and suggests that practices should be providing first aid training for horse owners, covering basic wound management and when to seek veterinary advice.
The survey, which was posted on social media groups for horse owners, showed they were most likely to call out a vet if their horse had a deep wound (96% of respondents). However, only a third would seek veterinary advice for a wound that is bleeding.
Vita, which makes the veterinary-exclusive Omnimatrix skin cream, said that 84% of owners keep a topical treatment for minor wounds in their first aid box, but some use barrier creams that do not provide an antiseptic environment.
Tara Evans RVN, Head of Sales at Vita, said: "It is great to see that owners are equipped with a first aid box for their horses. However, our survey highlights that many are not seeking veterinary advice, even if their horse is lame. This raises concerns over horses receiving appropriate treatment in a timely manner. There is an opportunity for practices to review first aid boxes with owners to ensure they're stocking appropriate supplies, and discuss appropriate wound management."
Vita has created an owner guide for wound management in horses which you can download and give to clients, here: https://www.vita-europe.com/animalhealth/news/wound-healing-in-horses/
The article argues that as the equine influenza (EI) vaccine supply returns to normal, there is sound scientific evidence why bi-annual vaccination schedules should be re-implemented promptly.
Whilst the scale and number of outbreaks has been relatively small since the introduction of mandatory EI vaccination by most competitive equestrian disciplines in the 1980s, disease events such as those experienced in the UK in 1989, 2003 and most recently in 2019 have demonstrated EI’s epidemic potential, even in vaccinated horse populations.
In their article 'Equine influenza bi-annual boosters: what does the evidence tell us?' Victoria Colgate and Richard Newton discuss what has been learnt from previous outbreaks and explain the evidence from mathematical models to show why bi-annual boosters are beneficial.
The authors say that epidemiological data from previous natural EI outbreaks have repeatedly demonstrated the impermanent nature of the protection provided by vaccination and observational field studies have repeatedly highlighted the potential for 12-monthly boosters to leave a vulnerable immunity gap at both the individual animal and population level.
Mathematical models of EI transmission confirm that six-monthly rather than annual EI booster vaccinations are preferable to establish and maintain effective population level immunity to EI.
Ideally vaccine strains should be updated in a timely manner to ensure inclusion of the most epidemiologically-relevant strains, however, this is a slow and expensive process for equine vaccine manufacturers.
In the absence of updated vaccine strains, bi-annual vaccination is strongly recommended to help compensate for antigenic drift between vaccine and circulating EI viral strains
Professor Celia Marr, Editor of the EVJ said: “Although the recent EI vaccine shortage has necessitated a temporary relaxation of competition vaccine schedules, we must now renew the message that six-monthly boosters are optimal and necessary.”
The Editorial can be found at https://beva.onlinelibrary.wiley.com/doi/10.1111/evj.13898 and is free to view.
Two related articles can be found here: https://beva.onlinelibrary.wiley.com/doi/10.1111/evj.13874 and here: https://beva.onlinelibrary.wiley.com/doi/10.1111/evj.13885
The publishers say that with a global donkey population estimated at around 46 million, it’s imperative for the veterinary profession to stay well-informed about the unique biology and disease susceptibility of this species.
The virtual collection addresses the previous shortfall of pathophysiological information, with articles on pharmacology, diagnostics, disease prevalence and management practices relating to donkeys as working, companion and production animals.
Preventative healthcare is addressed with a study of a companion population of donkeys in the UK and clinicians are encouraged to focus on client education, promotion of vaccination, regular dental care, strategic parasite control programmes and weight management.
Several papers address decision-making around treatment options, emphasising the need for a good understanding of the pharmacology of the available therapeutic agents in relation to donkeys and the pathophysiology of the diseases, as well as the value of pain assessment and control.
Another important aspect of disease detection and management is the availability of accurate diagnostics. Several papers address aspects of diagnostic testing, with emphasis on the caution that must be taken when extrapolating from horses because of the minimal data relating specifically to donkeys.
Donkeys are often described as silent carriers of, or as being more resistant to, infectious agents. Two articles demonstrate that they can in fact develop severe clinical signs when exposed to certain known equine pathogens, raising the importance of surveillance, accurate diagnosis, outbreak management, disease control and clear communication and education.
Less common conditions in donkeys as well as awareness of zoonotic risk are addressed within the collection, emphasising the value of owner-driven reporting as part of a disease surveillance and control programme to inform decision making on relevant interventions.
Professor Celia Marr, Editor of the EVJ, said: “This impressive collection shines a spotlight on the important advances that have been made to donkey medicine and welfare and helps us to identify the research gaps yet to be filled
“By sharing this work, we aim to improve disease prevention and enhance the welfare of donkeys around the world as well as highlight the continued importance of owner education and improve the public perception of this enduring species.”
The virtual issue can be found here: https://beva.onlinelibrary.wiley.com/doi/toc/10.1001/(ISSN)2042-3306.donkey-medicine-welfare.vi